Fig. 6From: Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapiesCopyright © 2018 Taylor & FrancisIn-vivo antitumor activity by CK/tLyp-1 liposomes. A The mechanism of antitumor effect by CK/tLyp-1 liposomes. B The active targeting of CK/tLyp-1 liposomes in vivo. C An increased Ca2+ level of A549 cell treated with CK/tLyp-1 liposomes. D An increased ROS level of A549 cells treated with CK/tLyp-1 liposomes for 72 h. E Effects on MMP observed in A549 cells. Reprinted with the permission from Ref [101].Back to article page